Related coverage linked through entity extraction aliases.
May 01, 2026
Datopotamab deruxtecan improved PFS and OS versus chemotherapy in advanced TNBC in TROPION-Breast02. Median PFS was 10.8 vs 5.6 months; OS was 23.7 vs 18.7 months. Published in Annals of Oncology.
Jun 13, 2026
HRP-Fusion improved pCR prediction in HER2-positive breast cancer at ESMO TAT Asia 2026; experts also reviewed emerging endometrial targets and equitable access to HER2 therapies.
May 22, 2026
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Mar 28, 2026
Sacituzumab tirumotecan demonstrated a median overall survival of 20.0 months versus 13.5 months with docetaxel in pretreated EGFR-mutated NSCLC patients. The phase 2 OptiTROP-Lung03 study showed a hazard ratio of 0.63 for overall survival benefit with the TROP2-directed antibody-drug conjugate.
Mar 10, 2026
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
Mar 02, 2026
Phase III trial demonstrates belzutifan plus lenvatinib significantly improved progression-free survival versus cabozantinib in previously treated renal cell carcinoma patients, while neoadjuvant studies show promise for locally advanced disease.
